Clinical Trials for Uterine Diseases

Currently registered clinical trials for Uterine Diseases from ClinicalTrials.gov. 32 recruiting, 50 total studies.

This content is for informational purposes only. Always consult a healthcare professional.

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Uterine Diseases from the ClinicalTrials.gov database.

Trial Summary

  • Total studies: 50
  • Recruiting: 32
  • Active, not recruiting: 5
  • Completed: 5
  • Other: 8

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT00050752 — Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment1130
Study TypeOBSERVATIONAL
ConditionsRenal Tumor Histology; Cutaneous Leiomyoma; Kidney Cancer

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop lei…

NCT01174121 — Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

StatusRecruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment332
Study TypeINTERVENTIONAL
ConditionsMetastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Interventions; ;

Background:

The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients’ tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know i…

NCT02956031 — Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

StatusRecruiting
PhaseN/A
SponsorUniversity of Pretoria
Enrollment1500
Study TypeOBSERVATIONAL
ConditionsCervical Cancer; High Grade Sil; CIN2
Interventions; ;

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low f…

NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorSeagen, a wholly owned subsidiary of Pfizer
Enrollment1006
Study TypeINTERVENTIONAL
ConditionsCarcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma
Interventions; ;

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid t…

NCT05581004 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorGenentech, Inc.
Enrollment450
Study TypeINTERVENTIONAL
ConditionsLocally Advanced or Metastatic Solid Tumors; NSCLC; HNSCC; Melanoma; TNBC
Interventions; ;

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, tr…

NCT05579366 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorGenmab
Enrollment884
Study TypeINTERVENTIONAL
ConditionsHigh Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer
Interventions; ;

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

NCT05564377 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

StatusRecruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment2900
Study TypeINTERVENTIONAL
ConditionsAdvanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm
Interventions; ;

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatmen…

NCT05768139 — First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorEli Lilly and Company
Enrollment880
Study TypeINTERVENTIONAL
ConditionsBreast Cancer; Solid Tumors, Adult
Interventions; ;

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations.

Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination…

NCT05554328 — Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

StatusRecruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment165
Study TypeINTERVENTIONAL
ConditionsRecurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions; ;

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

NCT05092022 — St. Joseph’s HPV Self-sampling: Offering a Self-sampling Option in Clinic

StatusRecruiting
PhaseN/A
SponsorMilton S. Hershey Medical Center
Enrollment50
Study TypeINTERVENTIONAL
ConditionsCervical Cancer Screening
Interventions

This study aims to evaluate the effectiveness of offering self-sampled human papillomavirus (HPV) tests in increasing participation in cervical cancer screening, compared to the standard of care clinician-sampled test. The primary study endpoints are (1) patients’ acceptability of self-sampled HPV tests vs. clinician-sampled test, and (2) patients’ completion of self-sampled HPV test. The secon…

NCT05950464 — Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

StatusRecruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment65
Study TypeINTERVENTIONAL
ConditionsRecurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma
Interventions; ;

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killi…

NCT05581121 — PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

StatusRecruiting
PhasePhase 3
SponsorInstitut Claudius Regaud
Enrollment510
Study TypeINTERVENTIONAL
ConditionsCervical Carcinoma; Adenocarcinoma; Adenosquamous Carcinoma
Interventions;

This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compared to patients staged with FDG-PET/CT only followed by chemoradiation.

The planned sample size is 510; including 200…

NCT06465069 — A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorEli Lilly and Company
Enrollment420
Study TypeINTERVENTIONAL
ConditionsMetastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer
Interventions

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT06535607 — Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

StatusRecruiting
PhasePhase 2
SponsorAstraZeneca
Enrollment257
Study TypeINTERVENTIONAL
ConditionsSub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy); Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy); Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy); Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions; ;

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

NCT06760819 — A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

StatusRecruiting
PhasePhase 2
SponsorBayer
Enrollment111
Study TypeINTERVENTIONAL
ConditionsAdvanced Solid Tumors; HER2 Mutation
Interventions

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.

In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutati…

NCT06952504 — A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

StatusRecruiting
PhasePhase 3
SponsorMerck Sharp & Dohme LLC
Enrollment1123
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer
Interventions; ;

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.

  • EC is a type of cancer that starts in the tissues inside the uterus (womb)
  • pMMR indicates that certain normal proteins are present in the cancer cells
  • Advanced means the cancer has spread locally or to other parts of the body (metastatic) and …

NCT07220512 — The Better, Harder, Faster, Stronger Study

StatusRecruiting
PhaseN/A
SponsorWake Forest University Health Sciences
Enrollment35
Study TypeOBSERVATIONAL
ConditionsFrailty at Older Adults; Ovarian Cancer; Endometrial Cancer; Cognitive Dysfunction; Neoadjuvant Chemotherapy
Interventions

The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.

NCT07114601 — A Study of LY4257496 in Participants With Cancer (OMNIRAY)

StatusRecruiting
PhasePhase 1
SponsorEli Lilly and Company
Enrollment421
Study TypeINTERVENTIONAL
ConditionsBreast Neoplasms; Colorectal Neoplasms; Prostate Neoplasm; Endometrial Neoplasms; Neoplasm Metastasis
Interventions; ;

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The s…

NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment500
Study TypeINTERVENTIONAL
ConditionsCervical Carcinoma; Human Papillomavirus Infection
Interventions; ;

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cerv…

NCT07166094 — Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer

StatusRecruiting
PhasePhase 3
SponsorGenmab
Enrollment660
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer; Recurrent or Progressive Endometrial Cancer
Interventions;

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician’s choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study.

The s…

NCT07336173 — Uterine Artery Doppler Indices and Uterocervical Angle Measurment in Prediction of Preterm Labor

StatusRecruiting
PhaseN/A
SponsorKafrelsheikh University
Enrollment125
Study TypeOBSERVATIONAL
ConditionsPreterm Labor
Interventions

The goal of this observational study is to evaluate the role of uterine artery doppler indices and uterocervical angle measurement in prediction of preterm labor .The main question it aims to answer is:

Does combination of both uterine artery doppler indices and uterocervical angle measurement increase sensitivity and specificity for prediction of established preterm labor ? Participants alrea…

NCT07198074 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

StatusRecruiting
PhasePhase 3
SponsorNational Cancer Institute (NCI)
Enrollment255
Study TypeINTERVENTIONAL
ConditionsAdvanced Endometrial Carcinoma; Recurrent Endometrial Carcinoma
Interventions; ;

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, ly…

NCT07306559 — A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

StatusRecruiting
PhasePhase 1
SponsorBoehringer Ingelheim
Enrollment187
Study TypeINTERVENTIONAL
ConditionsAdvanced Relapsed or Refractory Germ Cell Tumours; Advanced Relapsed or Refractory Endometrial Cancer; Advanced Relapsed or Refractory Ovarian Cancer
Interventions

This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining treatment options or if standard therapy is not suitable. The purpose of this study is to test increasing doses of BI 3820768 to find a dose that people with these types of cancer can tolerate and t…

NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.

StatusRecruiting
PhaseN/A
SponsorPapillex Inc.
Enrollment60
Study TypeINTERVENTIONAL
ConditionsCIN - Cervical Intraepithelial Neoplasia; CIN 1; CIN 2; HPV; Cervical Cells
Interventions;

The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is:

Is there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 18…

NCT07290517 — Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

StatusRecruiting
PhaseN/A
SponsorIndiana University
Enrollment100
Study TypeINTERVENTIONAL
ConditionsIUD; Abnormal Uterine Bleeding; Pain, Cervical
Interventions;

The goal of this clinical trial is to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between IUD insertions using a suction cervical stabilizer (new device, FDA approved, atraumatic) and single-tooth tenaculum (standard, traumatic). Our aims are to:

  • assess and compare patient-reported pain during IUD insertion between the Care…

NCT07406087 — Navigation Intervention for Adolescent and Young Adult Cancer Survivors

StatusRecruiting
PhaseN/A
SponsorKaiser Permanente
Enrollment25
Study TypeINTERVENTIONAL
ConditionsBreast Cancer; Ovarian Cancer; Cervical Cancer; Testicular Cancer; Colon Rectal Cancer
Interventions

The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KPSC). PLEASE NOTE: This study is awarded in two phases. The UG3 phase has been awarded for the firs…

NCT07690540 — DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER

StatusRecruiting
PhaseN/A
SponsorEuropean Institute of Oncology
Enrollment510
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer; Immune Checkpoint Inhibitors
Interventions

In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).

Despite these advances, responses to immunotherapy remain heterogeneous. Not all patients with mismatch repair-deficient (dMMR) tumors derive durable benefit, while a subset of mismatch repair-profic…

NCT07643012 — Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

StatusRecruiting
PhaseN/A
SponsorRutgers, The State University of New Jersey
Enrollment30
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer
Interventions

To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.

NCT07676461 — Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

StatusRecruiting
PhaseN/A
SponsorCentro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Enrollment150
Study TypeOBSERVATIONAL
ConditionsGastric Cancer; Colorectal Cancer; Breast Cancer; Cervical Cancer; Head and Neck Cancer (H&N)
Interventions

This is a prospective observational cohort study conducted at Fundación CTIC in Bogotá, Colombia. It characterizes the oral, fecal and intratumoral microbiome of Colombian adults with advanced solid tumors (gastric, colorectal, breast, cervical and head-and-neck cancer) who receive first-line immunotherapy as standard of care, and compares them with healthy volunteers. Using multi-omics (HiFi m…

NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

StatusRecruiting
PhasePhase 2
SponsorNew Mexico Cancer Research Alliance
Enrollment140
Study TypeINTERVENTIONAL
ConditionsEndometrial Endometrioid Adenocarcinoma; Endometrial Hyperplasia
Interventions; ;

This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometri…

NCT02741102 — Uterine Transplant in Absolute Uterine Infertility (AUIF)

StatusRecruiting
PhasePhase 2 / Phase 3
SponsorBrigham and Women’s Hospital
Enrollment3
Study TypeINTERVENTIONAL
ConditionsFemale Infertility
Interventions

This study will examine the feasibility of initiating a uterine transplant program for Absolute Uterine Factor Infertility (AUFI) at Brigham and Women’s Hospital. The investigators plan to screen 30 patients with a goal of enrolling 10 patients. (5 donors and 5 recipients) After careful screening, appropriate candidates will undergo IVF, Uterine Transplantation, Embryo Transfer, Pregnancy and D…

NCT07684508 — Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer

StatusRecruiting
PhaseN/A
SponsorManni Huang
Enrollment154
Study TypeINTERVENTIONAL
ConditionsHypofractionated Radiotherapy; Intensity-modulated Radiotherapy; Cervical Cancers
Interventions

To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer

Active, Not Recruiting

NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

StatusActive, not recruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment6452
Study TypeINTERVENTIONAL
ConditionsAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma
Interventions; ;

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at leas…

NCT02466971 — Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

StatusActive, not recruiting
PhasePhase 3
SponsorNational Cancer Institute (NCI)
Enrollment450
Study TypeINTERVENTIONAL
ConditionsAdvanced Vaginal Adenocarcinoma; Advanced Vaginal Adenosquamous Carcinoma; Advanced Vaginal Squamous Cell Carcinoma; Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma
Interventions; ;

This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemother…

NCT06452355 — Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage

StatusActive, not recruiting
PhaseN/A
SponsorKOKO Medical Inc.
Enrollment72
Study TypeINTERVENTIONAL
ConditionsPostpartum Hemorrhage; Immediate Postpartum Hemorrhage; Hemorrhage, Postpartum
Interventions

The purpose of this study is to evaluate the safety and effectiveness of the KOKO™ device in the control and reduction of primary abnormal postpartum uterine bleeding or hemorrhage.

NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

StatusActive, not recruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment500
Study TypeINTERVENTIONAL
ConditionsCervical Carcinoma; Human Papillomavirus Infection
Interventions; ;

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cerv…

NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

StatusActive, not recruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment500
Study TypeINTERVENTIONAL
ConditionsCervical Carcinoma; Human Papillomavirus Infection
Interventions; ;

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cance…

Not Yet Recruiting

NCT03626844 — Maternal Outcomes Following Manual Lysis of the Placenta.

StatusNot yet recruiting
PhaseN/A
SponsorHoly Family Hospital, Nazareth, Israel
Enrollment100
Study TypeINTERVENTIONAL
ConditionsThird Stage of Delivery
Interventions;

Comparison of maternal outcomes following manual lysis of placenta 15 vs 30 minutes after delivery. A primary outcome of the drop in hemoglobin will be compared between the two groups. Secondary outcomes include blood transfusion rate, maternal satisfaction, time to first breastfeeding, length of hospital stay, infection rate etc.

NCT07669363 — Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)

StatusNot yet recruiting
PhasePhase 2
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment230
Study TypeINTERVENTIONAL
ConditionsCervical Intraepithelial Neoplasia; Papillomavirus Infections
Interventions;

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surge…

NCT06810739 — The Women’s Screening and Self-Testing Program (PROMETA) Study

StatusNot yet recruiting
PhaseN/A
SponsorTulane University
Enrollment8445
Study TypeINTERVENTIONAL
ConditionsHuman Papilloma Virus Related Cervical Carcinoma
Interventions

This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-p…

NCT07688512 — Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR)

StatusNot yet recruiting
PhasePhase 4
SponsorStony Brook University
Enrollment180
Study TypeINTERVENTIONAL
ConditionsPostpartum Hemorrhage; Uterine Atony; Uterine Atony With Hemorrhage; Elective Cesarean Section
Interventions

The goal of this randomized, double-blind clinical trial is to learn if Oxytocin is most effective at achieving adequate uterine tone (important for preventing postpartum hemorrhage) when administered as a bolus or an infusion in patients at high-risk for postpartum hemorrhage in elective cesarean sections. The main questions that will be answered are:

  1. Is Oxytocin bolus more effective than …

NCT07684599 — A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

StatusNot yet recruiting
PhasePhase 3
SponsorGlaxoSmithKline
Enrollment610
Study TypeINTERVENTIONAL
ConditionsNeoplasms, Endometrial
Interventions; ;

The purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug combination is safe and tolerated well by participants compared to the usual care and will help us better understand i…

NCT07688122 — Web-Based Gamification in Postpartum Hemorrhage Management Education Among Midwifery Students

StatusNot yet recruiting
PhaseN/A
SponsorMersin University
Enrollment128
Study TypeINTERVENTIONAL
ConditionsHemorrhage Management Training; Gamification in Health Education
Interventions;

This study was designed to compare the effects of web-based gamification and online classical teaching methods on knowledge level, motivation toward instructional materials, clinical self-efficacy, and satisfaction in midwifery students receiving postpartum hemorrhage management education.

Enrolling by Invitation

NCT07237932 — Adenomyosis Clinical, Imaging and Histopathology

StatusEnrolling by invitation
PhaseN/A
SponsorKafrelsheikh University
Enrollment32
Study TypeOBSERVATIONAL
ConditionsAdenomyosis

The goal of this clinical trial is to identify and compare the results of imaging studies and evaluating adenomyosis features and post hysterectomy results and their clinical relievants as well as to describe classification for adenomyosis based on one or a combination of clinical, imaging and histopathological features.

Main questions it aim to answer:

What’s the relation between clinical sy…

Completed Trials

NCT00087685 — RAD001 in Recurrent Endometrial Cancer Patients

StatusCompleted
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Enrollment35
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer
Interventions

The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth of tumors in patients who have recurrent endometrial cancer. The safety of this drug will also be studied.

Objectives:

Primary Objective:

1. To determine the efficacy of RAD001 in patients with progressive or recurrent endometrial cancer.

Secondary Objective:

  1. To determine the nature and degree …

NCT05462951 — Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

StatusCompleted
PhaseN/A
SponsorDenise Fabian
Enrollment19
Study TypeOBSERVATIONAL
ConditionsUterine Cervix Cancer
Interventions

This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.

NCT07689136 — Timing of Thromboprophylaxis After Postpartum Hemorrhage

StatusCompleted
PhaseN/A
SponsorUniversity Tunis El Manar
Enrollment236
Study TypeOBSERVATIONAL
ConditionsPostpartum Hemorrhage; Venous Thromboembolism; Pulmonary Embolism; Deep Vein Thrombosis
Interventions

Postpartum hemorrhage is a leading cause of maternal morbidity and mortality worldwide. Women who experience severe postpartum hemorrhage are at increased risk of both recurrent bleeding and venous thromboembolism. The optimal timing for starting pharmacological thromboprophylaxis after postpartum hemorrhage remains uncertain.

This retrospective observational cohort study was conducted at the …

NCT07398313 — Effect of Prehabilitation on Recovery Outcomes in Post-Surgical Cervical Cancer Women

StatusCompleted
PhaseN/A
SponsorSaveetha University
Enrollment34
Study TypeINTERVENTIONAL
ConditionsCervical Adenocarcinoma; Hysterectomy; Cervical Cancer
Interventions;

This parallel-group randomized controlled trial evaluated the effectiveness of a four-week multimodal prehabilitation programme on pelvic function and quality of life among women with cervical cancer undergoing radical hysterectomy. Thirty-nine eligible participants were randomly allocated to either the intervention group or the control group. The intervention group received a supervised multim…

NCT07229573 — The Effectiveness of Serious Game-Based Training for Nursing Students in Postpartum Haemorrhage Management

StatusCompleted
PhaseN/A
SponsorSakarya University
Enrollment70
Study TypeINTERVENTIONAL
ConditionsGamification; Gamification in Health Education; Nurse Education; Nursing Students; Postpartum Hemorrhage
Interventions

This randomised controlled trial aims to evaluate the effectiveness of serious game-based training for postpartum haemorrhage (PPH) management among third-year nursing students. The study employs a pre-test-post-test design with two parallel groups: an experimental group (game-based education) and a control group (traditional education). The sample size was determined by power analysis to be 70…

Other (Terminated)

NCT04527900 — The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

StatusTerminated
PhasePhase 2
SponsorUniversity of Maryland, Baltimore
Enrollment2
Study TypeINTERVENTIONAL
ConditionsEndometrial Cancer
Interventions;

A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study